← All trials
NCT04355286
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Jul 31, 2020
- Completion date
- Sep 30, 2020
- First posted
- Apr 21, 2020
- Last posted
- Apr 21, 2020
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- DSMLead sponsor
- Spaulding Clinical Research Inc.Collaborator
- Spaulding Clinical Research Inc.Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.